Product Description
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cixutumumab)
Mechanisms of Action: IGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Alveolar Rhabdomyosarcoma|Squamous Cell Carcinoma|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Male Breast Cancer|Embryonal Rhabdomyosarcoma|Adrenocortical Carcinoma|Hemangiosarcoma|Primitive Neuroectodermal Tumors|Neurofibrosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Wilms Tumor|Colorectal Cancer|Breast Cancer|Retinoblastoma|Alveolar Soft Part Sarcoma|Sarcoma, Ewing|Liver Cancer|Adenocarcinoma|Leiomyosarcoma|Prostate Cancer|Osteosarcoma|Synovial Sarcoma|Rhabdomyosarcoma|Liposarcoma|Uveal Melanoma|Hepatocellular Carcinoma|Neuroblastoma|Pancreatic Cancer|Gliosarcoma|Embryonal Carcinoma|Hepatoblastoma|Soft Tissue Cancer|Neuroendocrine Carcinoma|Small Cell Lung Cancer|Kidney Cancer|Mesothelioma|Neuroendocrine Tumors|Bronchiolo-Alveolar Adenocarcinoma|Large Cell Carcinoma|Gastrointestinal Cancer|Peritoneal Cancer|Esophageal Cancer
Phase 1: Neuroendocrine Carcinoma|Glucagonoma|Somatostatinoma|Insulinoma|Gastrointestinal Cancer|Islet Cell Carcinoma|Oncology Solid Tumor Unspecified|Gastrinoma|Malignant Carcinoid Syndrome|Carotid Body Tumor|Carcinoma, Merkel Cell|Pancreatic Cancer|Neuroendocrine Tumors|Paraganglioma|Carcinoid Tumor|Medullary Carcinoma|Primitive Neuroectodermal Tumors|Sarcoma, Ewing|Thrombocytopenia|Peripheral Neuroectodermal Tumors, Primitive|Hyperglycemia|Neutropenia|Hypertension|Anemia|Glioma|Hepatocellular Carcinoma|Pinealoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2011-03039 | P2 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer |
2018-08-15 |
|
| BATTLE-FL | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2017-08-15 |
|
| NCI-2011-01917 | P2 |
Completed |
Small Cell Lung Cancer |
2016-11-15 |
|
| 10-C-0146 | P2 |
Completed |
Mesothelioma|Peritoneal Cancer |
2016-08-13 |